



ALEXIUM

ALEXIUM INTERNATIONAL GROUP LIMITED
APPENDIX 4E PRELIMINARY FINAL REPORT
For the Year Ended 30 June 2020

ABN 91 064 820 408 PRESENTED IN US DOLLARS

1.0 Reporting Period

Year ended 30 June 2020

Previous corresponding period: Year ended 30 June 2019

2.1 Revenue from ordinary activities up **20.2%** to **6,078,857**

2.2 Loss from ordinary activities for the period after tax attributable to members down **(11.7%)** to **(6,125,476)**

2.3 Net loss for the period attributable to members down **(11.7%)** to **(6,125,476)**

2.4 Dividends	Amount per security	Franked amount per security
Final dividend	Nil	Nil
Interim dividend	Nil	Nil

2.5 Record date for determining entitlements to the dividends Not applicable

2.6 Brief explanation of any figures reported above to enable the figures to be understood:

Refer to Annual Report

3. Consolidated Statement of Comprehensive Income

	2020 US\$	2019 US\$
Revenue	6,078,857	5,059,039
Cost of sales	(3,765,758)	(3,453,297)
Gross Profit	2,313,099	1,605,742
Administrative expenses	(3,000,901)	(3,609,008)
Sales and marketing expenses	(935,575)	(1,282,435)
Occupancy expenses	(553,061)	(557,287)
Research and development costs	(353,285)	(413,074)
Other expenses	(182,525)	(547,111)
Operating expenses	(5,025,347)	(6,408,915)
Loss before finance costs	(2,712,248)	(4,803,173)
Interest expense	(1,882,358)	(2,793,604)
Loss on debt extinguishment	(1,522,003)	-
Gain / (Loss) on embedded derivative	(27,523)	629,642
Interest received	18,656	27,614
Total finance costs	(3,413,228)	(2,136,348)
Loss before tax	(6,125,476)	(6,939,521)
Tax expense	-	-
Loss for the year after tax	(6,125,476)	(6,939,521)
Other comprehensive income - Exchange differences on translation of foreign operations which may subsequently be reclassified to profit or loss	(188,947)	(31,893)
Total comprehensive loss for the year	(6,314,423)	(6,971,414)
Loss for the year attributable to members of the group	(6,125,476)	(6,939,521)
Total comprehensive loss for the year attributable to members of the group	(6,314,423)	(6,971,414)
Basic and diluted loss per share (cents)	(1.26)	(2.01)

4. Consolidated Statement of Financial Position

	2020 US\$	2019 US\$
Current Assets		
Cash and cash equivalents	4,741,251	3,843,343
Trade and other receivables	979,680	962,023
Inventories	921,554	1,153,453
Other current assets	41,500	74,917
Total Current Assets	6,683,985	6,033,736
Non-Current Assets		
Other financial assets	17,682	17,982
Property, plant and equipment	1,095,886	1,727,001
Intangible assets	2,678,615	1,778,484
Right of use asset	1,194,166	-
Total Non-Current Assets	4,986,349	3,523,467
Total Assets	11,670,334	9,557,203
Current Liabilities		
Trade and other payables	905,514	1,558,500
Lease liabilities	136,753	170,974
Total Current Liabilities	1,042,267	1,729,474
Non-Current Liabilities		
Borrowings	2,440,230	6,786,592
Derivative liability	1,810,494	658,141
Lease liabilities	949,786	-
Total Non-Current Liabilities	5,200,510	7,444,733
Total Liabilities	6,242,777	9,174,207
Net Assets	5,427,557	382,996
Equity		
Contributed equity	65,943,807	54,367,832
Reserves	(927,236)	5,078,244
Accumulated losses	(59,589,014)	(59,063,080)
Total Equity	5,427,557	382,996

5. Consolidated Statement of Cash Flows

	2020 US\$	2019 US\$
Cash flow from operating activities		
Receipts from customers and other income	6,422,456	4,844,649
Payments to suppliers and employees	(8,762,060)	(8,052,450)
Interest received	18,656	27,614
Interest and other costs of finance paid	(906,208)	(1,219,230)
Goods & services tax received from ATO	52,021	57,876
Net cash flows (used in) operating activities	(3,175,135)	(4,341,541)
Cash flows from investing activities		
Purchase of property, plant and equipment	(102,281)	(90,683)
Purchase of other non-current assets	-	(60,000)
Proceeds from disposal of property, plant and equipment	430	-
Payments for development costs	(1,098,264)	(987,153)
Net cash flows (used in) investing activities	(1,200,115)	(1,137,836)
Cash flows provided by financing activities		
Proceeds from issue of ordinary shares	11,768,661	-
Proceeds from borrowings	4,071,918	-
Transaction costs related to issues of shares	(634,502)	-
Transaction costs related to issues of convertible notes	(111,952)	-
Repayment of borrowings	(9,587,713)	(1,258,696)
Net cash flows from/ (used in) financing activities	5,506,412	(1,258,696)
Net increase / (decrease) in cash and cash equivalents	1,131,162	(6,738,073)
Cash and cash equivalents at beginning of year	3,843,343	10,641,763
Effect of exchange rate changes on cash and cash equivalents	(233,254)	(60,347)
Cash and cash equivalents at end of year	4,741,251	3,843,343

6. Consolidated Statement of Changes in Equity

	Contributed equity \$	Options & Warrants Reserve \$	Performance Rights Reserve \$	Foreign Currency Translation Reserve \$	Consolidated Accumulated Losses \$	Total \$
Balance at 1 July 2019	54,367,832	5,634,968	1,021,204	(1,577,928)	(59,063,080)	382,996
Loss for the period	-	-	-	-	(6,125,476)	(6,125,476)
Foreign currency translation	-	-	-	(188,947)	-	(188,947)
Total comprehensive income / (loss)	-	-	-	(188,947)	(6,125,476)	(6,314,423)
Transactions with owners in their capacity as owners:						
Reclass to accumulated losses	-	(4,992,832)	(606,710)	-	5,599,542	-
Issued capital	11,768,661	-	-	-	-	11,768,661
Capital raising costs	(634,502)	-	-	-	-	(634,502)
Performance rights issued	-	-	113,569	-	-	113,569
Performance rights exercised	427,199	-	(427,199)	-	-	-
Share-based payments	14,617	-	12,705	-	-	27,322
Warrants outstanding	-	83,934	-	-	-	83,934
Balance at 30 June 2020	65,943,807	726,070	113,569	(1,766,875)	(59,589,014)	5,427,557

Balance at 1 July 2018	54,367,832	5,634,968	652,423	136,430	(53,806,617)	6,985,036
Change in accounting estimate ¹	-	-	-	(1,695,787)	1,695,787	-
Loss for the period	-	-	-	-	(6,939,521)	(6,939,521)
Foreign currency translation	-	-	(593)	(18,571)	(12,729)	(31,893)
Total comprehensive income / (loss)	-	-	(593)	(18,571)	(6,952,250)	(6,971,414)
Transactions with owners in their capacity as owners:						
Issued Capital	-	-	-	-	-	-
Capital Raising Costs	-	-	-	-	-	-
Performance Rights Expense	-	-	280,941	-	-	280,941
Options Exercised	-	-	-	-	-	-
Share-based payment in lieu of salary	-	-	88,433	-	-	88,433
Balance at 30 June 2019	54,367,832	5,634,968	1,021,204	(1,577,928)	(59,063,080)	382,996

- (1) Accumulated Losses and Foreign Currency Reserve balances at 1 July 2018 were adjusted from the 30 June 2018 balances reported in the FY 2018 Annual Report to reflect a reallocation of \$1,695,786 between the two accounts related to the foreign currency translation.

7.0 Dividends

Date dividend is payable	Not applicable
Record date to determine entitlement	Not applicable
If it is a final dividend, has it been declared?	Not applicable

	Amount per security	Franked amount per security at 30%	Amount per security of foreign source dividend
8.0 Dividend distribution			
Final dividend: Current year	Nil	Not applicable	Not applicable
Interim dividend: Current year	Nil	Not applicable	Not applicable

9.0 Net tangible asset backing	2020	2019
Net tangible asset backing (deficiency) per ordinary share	0.43	(0.40)

10. Details of entities over which control has been gained or lost during the period, including the following.

Not applicable

11. Details of associates and joint venture entities including the following.

Not applicable

12. Any other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.

Refer to annual report

13. Foreign entities set of accounting standards used in compiling the report (IAS)

IFRS

14. Commentary on the results for the period

Refer to annual report

14.1 Earnings per share (EPS)	2020	2019
Basic loss per share (cents)	(1.26)	(2.01)
14.2 Returns to shareholders	2020	2019
Ordinary securities	-	-
Preference securities	-	-
Other equity instruments	-	-
Total	-	-

15. Compliance statement

This report is based on accounts to which one of the following applies.

- ☒ The accounts have been audited.
 ☐ The accounts have been subject to review.
 ☐ The accounts are in the process of being audited or subject to review.
 ☐ The accounts have not yet been audited or reviewed.



Sign here:

Date: 28 August 2020

Dr. Robert Brookins
Chief Executive Officer